Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial

The goal of this clinical trial is to test curcumin as an adjunct treatment in patients with cervical cancer receiving standard-of-care palliative radiation. The main questions it aims to answer are: 1. Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients feasible? Is conducting this study feasible? 2. Does adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients improve therapeutic responses? 3. Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients safe? 4. How much curcumin is absorbed into the body and how long will it stay in the body? Participants will: i. Take 250 mg curcumin capsules four times per day for 4-6 weeks in addition to the prescribed palliative radiotherapy. ii. Provide blood and urine samples for laboratory tests. iii. Provide blood samples to measure curcumin levels in their body. iv. Obtain CT-scan to measure their tumor response. v. Complete questioners to measure improvements to their quality of life, if any.

NCT Number	NCT05947513
Lead Sponsor	Addis Ababa University Collaborators: Akay Natural Ingredients Private Limited
Conditions	Cervical Cancer
Enrollment	27 participants
Start Date	2025-04-10
Primary Completion	2026-02 (estimated)
Study Completion	2026-04 (estimated)
Updated on ClinicalTrials.gov	2025-04-20